Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-D

First Page		Document Content
Date: 2018-04-10 18:00:06		Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-D Add to Reading List Source URL: selectabio.com Download Document from Source Website File Size: 1,35 MB Share Document on Facebook